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Abstract
Germ line BRCA1 and/or BRCA2 mutations were screened in 50 Turkish breast and/or ovarian cancer patients composed of
hereditary, familial, early onset and male cancer groups. Genomic DNA samples were tested by heteroduplex analysis and DNA
sequencing. Two truncating BRCA2 mutations, one novel (6880 insG) and one previously reported (3034 delAAAC), were found in
two out of six (33%) hereditary breast and/or ovarian cancer patients. A novel truncating (1200 insA) and a missense (2080A!G)
BRCA1 mutation was found in two of 27 (7%) individuals in the early onset group. A total of four (8%) disease-causing mutations
in 50 breast cancer patients were identified in BRCA1 and BRCA2 genes. In addition, five BRCA1 sequence variants have been
identified in 23 patients. These results indicate that BRCA1 and BRCA2 genes are involved in some, but not all, forms of hereditary
predisposition to breast cancer in the Turkish population. # 2000 Published by Elsevier Science Ltd.
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1. Introduction
Breast cancer is one of the most common malig-
nancies aecting women [1] (http://www.nci.nih.gov/
public/factbook98/incidence.htm). Inherited gene muta-
tions may be responsible for 5–10% of breast cancer
cases [1–3]. Ovarian cancer is also known to have a
familial component [4].
Two genes associated with inherited predisposition to
breast and/or ovarian cancer have been identified. These
are BRCA1 on chromosome 17q12-21 [1], and BRCA2
on chromosome 13q12-13 [5]. Population genetics stu-
dies aimed at determining the relative contributions of
these genes in hereditary breast and/or ovarian cancer
have shown a wide variation among dierent popula-
tions [6]. For example, in families with three or more
cases of female breast and/or ovarian cancer, BRCA1
mutations are as low as 9% in Iceland and as high as
79% in Russia. A similar variation has been docu-
mented for BRCA2 mutations as well, which can be
exemplified by 8% in Finland and 64% in Iceland. In
aected women before the age of 45 years with a first-
degree relative, BRCA1 mutations account for 7% of
the families [7]. In families with both male and female
breast cancer, BRCA2 mutations were documented in
19% of North American, 33% of Hungarian and 90%
of Icelandic populations [6]. In isolated male breast
cancer cases, a very low frequency of BRCA2 mutations
has been reported [8]. In early onset breast and/or
ovarian cancer patients not selected for family history,
4–9% have BRCA1, and 2–8% have BRCA2 mutations
[6,7].
Breast cancer is among the most common malig-
nancies in Turkish women [9]. The frequency and the
types of germ line mutations involved in Turkish breast/
ovarian cancers are not well known. In order to deter-
mine the contributions of BRCA1 and BRCA2 muta-
tions to the development of breast and/or ovarian
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cancer in the Turkish population, we screened pre-
selected regions of these genes in four groups of patients
composed of hereditary and familial cancer, as well as
early onset and male breast cancer.
2. Patients and methods
2.1. Families
We analysed a total of 50 genomic DNA samples
isolated from the white blood cells of breast cancer
patients. The samples were collected from the Medical
Schools of Hacettepe, Istanbul, Ankara Universities,
and Ankara Oncology Hospital. Informed consent was
obtained from all participants. Each proband was inter-
viewed for pedigree construction including information
concerning the family history of breast, ovarian and
other cancers. Based on the pedigree analysis, patients
were divided into four groups. Available medical and
pathological records were reviewed to verify the diag-
noses. The phenotypical characteristics of the families
included in the study are summarised in Table 1 and the
pedigrees for the hereditary and familial groups in Fig. 1.
2.2. Polymerase chain reaction (PCR) and heteroduplex
analysis
DNA isolation was performed from 1 ml peripheral
blood by phenol/chloroform extraction [10]. Exons 2, 5,
11 (10 overlapping fragments), 13, 20, 24 of BRCA1,
and exon 11 (7 overlapping fragments) of BRCA2 were
screened for mutations by heteroduplex analysis using
previously reported primers [11,12]. PCR was per-
formed in a total volume of 10 ml, with 10 buer, 1.5
U Taq polymerase, 1.5 mM MgCl2, 200 mM dNTP, 10
pmol of each primer and 1mCi of [32P] dCTP (specific
activity 3000 Ci/mmol). PCR conditions were as fol-
lows: 94C for 3 min, 30 cycles of 30 s at 94C, 30 s at
55C and 30 s at 72C. Ten minutes of 72C was added
as the extension step. PCR products were denatured at
95C for 10 min, and left at 37C for 2 h. five microlitres
of PCR products were loaded on to 6% native poly-
acrylamide gels and run at 400 V for 16 h. The gels were
then dried and exposed to X-ray films overnight at
ÿ80C.
2.3. Sequencing
Fragments that showed an alteration in the hetero-
duplex analysis were re-amplified for sequencing. The
primer pairs for BRCA1 did not change. However,
BRCA2 exon 11 was subdivided into 26 overlapping
fragments for DNA sequencing reactions [12]. PCR was
performed in a total volume of 50 ml, with 10 buer,
1.5 U Taq polymerase, 1.5 mM MgCl2, 200 mM dNTP
and 10 pmol of each primer. PCR conditions were as
follows: 94C for 3 min, 30 cycles of 30 s at 94C, 30 s at
55C and 30 s at 72C. 10 min of 72C was added as the
extension step. PCR products were sequenced using
Amersham Thermosequenase Dye Terminator cycle
sequencing kit, according to the manufacturer’s
instructions, and analysed on an ABI 377 automated
DNA sequencer or ABI 310 Genetic Analyzer.
Table 1
Phenotypes and mutations identified in Turkish hereditary, and familial breast and breast–ovarian cancer groups
Group Family Mutation Predicted
eect
Age of
proband
(years)
Relatives with breast
and/or ovarian cancer
Other cancers in
the relatives
1st degree 2nd degree 3rd degree
Hereditary cancer 1 – – 45 2 (52, 53) 1 (53) 2 Liver (54)
2 BRCA2 6880 insG Stop2224 25a 1 (25) – – –
10 – – 32a 1 (62) – 1 (35) Colon
18 – – 37 1 (63) 1 (55) 1 (45) –
20 – – 53b 2 (57, 60) – – Endometrium (58)
22 BRCA2 3034 delAAAC Stop958 76 2 (42, 77) – – Stomach (68)
Familial cancer 3 – – 50 1 (39) – – Lung, gall bladder,
liver, leukaemia
4 – – 50 1 (29) – – –
6 – – 51 1 (35) – – Liver
7 – – 37 1 (41) – – Colon (63)
19 – – 38 1 (55) – 1 (40) –
48 – – 31 1 (63) – 1 (45) –
61 – – 36 1 (50) – – Colon (35, 48)
a Bilateral breast cancer.
b Breast and ovarian cancer. The number in parentheses indicates the age at diagnosis.
Hereditary group consisted of probands with at least two aected first degree relatives, and those with bilateral breast cancer and one aected
first-degree relative. Patients who have one aected first-degree relative diagnosed with breast cancer were in the familial group.
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Mutations identified by direct sequencing were subjected
to confirmatory analysis. For this purpose, PCR products
were cloned into Promega pGEM TEasy TA cloning
kit, according to the manufacturer’s directions. Several
miniprep plasmid DNA samples for each patient were
isolated by phenol chloroform extraction and sequenced
using the Perkin Elmer Big Dye cycle sequencing kit.
3. Results
Germ line BRCA1 and/or BRCA2 mutations were
screened in 50 breast and/or ovarian cancer patients
from Turkey. We employed a BRCA1 and BRCA2
mutation screening strategy which is based on the loca-
lisation of previously reported mutations in these genes.
Fig. 1. Pedigrees of the hereditary (a) and familial (b) cancer groups. Ages of the individuals are indicated below the symbols, the age at diagnosis of the
aected individuals are indicated in parentheses. Br, breast; Br and Ov, breast and ovarian; C, colon; E, endometrial; G, gall bladder; L, Leukaemia;
Lg, lung; Li, liver, Ov, ovarian; S, stomach. (continued overleaf).
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Selected regions of BRCA1 (exons 2, 5, 11, 13, 20 and
24), and BRCA2 (exon 11) were subjected to hetero-
duplex analysis, and altered fragments were further
analysed by DNA sequencing. According to the BIC
database (http://www.nhgri.nih.gov/Intramural_research/
Lab_transfer/Bic/index.html), these BRCA1 and
BRCA2 regions harbour 80% and 45% of the muta-
tions, respectively.
The patients were divided into four groups of heredi-
tary (n=6) breast/ovarian cancer, and familial (n=7),
early onset (n=27) or male (n=10) breast cancer. The
selected regions of both BRCA1 and BRCA2 genes were
analysed in all four groups.
Nine dierent sequence alterations (seven for BRCA1
and two for BRCA2) were identified in 25 patients. In
BRCA2, one previously reported deletion (3034
Fig. 1. (continued).
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delAAAC), and one novel insertion (6880 insG) (Fig.
2a) type of frameshift mutations leading to protein
truncation were observed. In BRCA1, one novel frame-
shift mutation (1200 insA) (Fig. 2b), one novel missense
mutation (2080 A!G; K654E) (Fig. 3a), and one novel
silent mutation (1013 T!C; N298N) were identified. In
addition, four previously reported BRCA1 polymorph-
isms (one silent and three missense mutations) were also
found in these Turkish breast cancer patients (see Table
2).
The hereditary group consisted of patients with at
least two aected first-degree relatives, and those with
bilateral breast cancer plus one aected first-degree
relative (Table 1). We identified two BRCA2 frameshift
mutations, 6880 insG (Fig. 2a) and 3034 delAAAC, in
two of the six families (33%) in this group. Interestingly
no BRCA1 mutation was found except for a previously
reported frequent polymorphism which is an A to G
transition at nucleotide 3667 in three (50%) families.
Patients who have one aected first-degree relative
also diagnosed with breast cancer constitute the familial
group. No frameshift or nonsense BRCA1 or BRCA2
mutation was observed. However, previously reported
BRCA1 polymorphisms 3667 A!G in three (43%), and
2731 C!T in 2 (29%) patients were present. In addi-
tion, a novel silent BRCA1 mutation (1013 T!C) was
identified in 1 patient.
Women diagnosed as having breast cancer before the
age of 35 years, none of whom were selected on the
basis of family history status were in the early onset
group (Table 3). A novel BRCA1 frameshift mutation,
1200 insA (Fig. 2b), was identified in 1 patient. In addi-
tion, five dierent BRCA1 sequence alterations were
observed in 12 patients. These alterations include one
novel (1013 T!C), and four previously reported poly-
morphisms (see Table 2). The 3667 A!G polymorph-
ism was observed in 33% (9/27) of patients.
Interestingly each allele of BRCA1 displayed a missense
Fig. 2. (a) DNA sequence analysis of familial breast cancer case 96/2
with a novel BRCA2 mutation (6880 insG). (b) DNA sequence of
patient 97/641 a novel BRCA1 mutation (1200 insA).
Fig. 3. (a) DNA sequence of patient 97/670 showing the BRCA1 allele
with missense mutation 2080 A!G. (b) DNA sequence of patient 97/
670 showing the other BRCA1 allele with two polymorphisms, 2196
G!A and 2201 C!T. Arrow indicates the mutations.
Table 2
Mutations and polymorphisms identified in turkish breast and breast–ovarian cancer patients
Number of
times recorded
Gene Exon NT Codon Base change AA change Designation Mutation type Mutation eect
1 BRCA2 11 3034 938 delAAAC Stop 958 3034 delAAAC F F
1 BRCA2 11 6880 2218 insG Stop 2224 6880 insG F F
1 BRCA1 11 1200 361 insA Stop 368 1201 insA F F
1 BRCA1 11 2080 654 A to G Lys to Glu K654E M M
1 BRCA1 11 2196 693 G to A Asp to Asn D693N M P
3 BRCA1 11 2731 871 C to T Pro to Leu P871L M P
16 BRCA1 11 3667 1183 A to G Lys to Arg K1183R M P
2 BRCA1 11 1013 298 T to C Asn to Asn N298N P P
1 BRCA1 11 2201 694 C to T Ser to Ser S694S P P
F, frameshift; M, missense; P, polymorphism; NT, nucleotide; Lys, lysine; Glu, glutamine; Asp, aspartic acid; Pro, proline; Leu, leucine; Arg,
arginine; Asn, asparagine; Ser, serine; AA, amino acid.
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mutation in 1 patient (Fig. 3a and b): a previously
described rare polymorphism (2196 G!A; D693N) and
a novel missense mutation (2080 A!G; K654E). This
patient also carried a silent mutation (2201 C!T) co-
segregating with the 2196 G!A mutation. The phase of
these transitions was determined by cloning of the
patient’s PCR product and sequencing of the multiple
clones. This finding establishes that sequence alterations
2080 A!G and 2196 G!A, which lead to amino acid
substitutions K654E and D693N, respectively, were
independently inherited. Sequence analysis showed that
the 2080A!G mutation was absent in 100 independent
alleles from a control population. The novel K654E
substitution is not in a conserved residue but when the
BRCA1 sequence is subjected to secondary structure
prediction programs SOPMA and GOR4 (http://pbil.
ibcp.fr/cgi-bin/secpred) this region forms a short alpha
helix, carrying four consecutive lysine residues. Even
though the Lys to Glu substitution may increase the
helix stability, it neutralises the positive charges on the
helix, which may have an important role for the structure
and function of the protein. Occurrence of two mutant
alleles in the same patient with a sporadic early onset
malignancy (age 27 years) suggests that these mutations
may be involved in the development of breast cancer.
The fourth group we studied was composed of iso-
lated male breast cancer cases. We were unable to detect
mutations in the selected regions of BRCA1 and
BRCA2 genes in this group. The age of the male breast
cancer cases is shown in Table 4.
In conclusion, among 50 Turkish breast cancer cases,
we detected two (4%) BRCA2 and one (2%) BRCA1
disease-causing frameshift mutations. In addition, one
(2%) missense BRCA1 mutation, and five BRCA1
polymorphisms in 23 patients (46%) were identified.
4. Discussion
A wide variation in the BRCA1 and BRCA2 mutation
spectrum and frequency has been reported for dierent
populations [6]. The results of our Turkish data are
summarised in Table 5. In the hereditary breast cancer
group, BRCA2 mutations accounted for 33% of cases.
This frequency is rather high and similar to the Icelan-
dic population. Interestingly, BRCA1 mutations in our
study group appear to be rare — if not exceptional,
similar to patients from Iceland, Norway and Japan.
However, in a recently published paper, Balci and col-
leagues reported BRCA1 mutations in 2 out of 5 her-
editary breast cancer cases compared with one BRCA2
mutation [13]. We did not detect BRCA1 or BRCA2
mutations in the familial breast cancer cases. Our
BRCA1 data confirm the observations of Malone and
colleagues who identified BRCA1 mutations in only 7%
of cases [7]. To the best of our knowledge, BRCA2
mutations in this group have not been reported pre-
viously. Although we did not screen all exons of BRCA2
our observations suggest that the BRCA2 gene is also
infrequently involved in familial breast cancer. The
results obtained from this study indicate that BRCA1
and BRCA2 genes are involved in the development of
some, but not all, hereditary breast cancers in the
Turkish population as reported for other populations
[14,15].
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Age of male breast cancer cases
Case Age (years)
97/631 71
97/694 73
97/695 57
97/699 56
98/3 66
98/13 56
98/14 40
98/15 70
98/16 77
98/59 68
Table 5
BRCA1 and BRCA2 mutation frequencies in dierent patient groups
Patient groups BRCA1 BRCA2
n (%) n (%)
Hereditary breast and/or ovarian cancer (n=6) 0 2 (33)
Familial breast and/or ovarian cancer (n=7) 0 0
Early onset breast cancer (n=27) 1 (4) 0
Male breast cancer (n=10) 0 0
Table 3
Age of early-onset breast cancer cases
Case Age (years) Case Age (years)
96/5 33 97/656 35
96/10 32 97/661 26
97/114 34 97/662 36
97/270 29 97/670 27
97/343 35 97/674 27
97/344 32 97/681 33
97/359 32 97/682 36
97/472 32 97/683 32
97/473 31 97/684 29
97/508 26 97/703 27
97/632 31 98/12 27
97/639 38 98/17 29
97/641 31 98/18 28
97/655 31
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